-
The next city Novo Nordisk is approaching a record high! Can medical device ETFs get in on the action?
On October 10, Novo Nordisk announced that the Phase 3 clinical trial of Simeaglutide for the treatment of kidney failure and chronic kidney disease in patients with type 2 diabetes was stopped nearly ... -
Novo Nordisk US stocks rose 2% before trading
On November 2nd local time, Novo Nordisk's US stock market rose 2% before trading. On the news, Novo Nordisk's Wegovy sales in the third quarter were 9.65 billion Danish kroner, with an expected 8.07 ... -
Lilly diabetes drug is approved for adult weight loss in the United States, and its price is 20% cheaper than that of Pinot Noir and Nordisk
GLP-1 drugs have gained significant players in the field of weight loss, with prices 20% cheaper than Nuo and Nordsmiglutide. On November 8 local time, Eli Lilly, a multinational pharmaceutical giant ... -
Lilly's Heavyweight Weight Loss Drug Approved to Compete head-on with Novo Nordisk
On November 8th, the US FDA approved Lilly's Tirzepatide for weight loss indications (trade name: Zepbound), becoming another approved weight loss drug after Novo Nordisk's Wegovy and paving the way ... -
Out of stock of 'weight loss pills'? Giant Novo Nordisk Announces Full Capacity Expansion
Novo Nordisk, the giant, has announced a full expansion of its production, reigniting market enthusiasm. Novo Nordisk stated that it plans to invest over 42 billion Danish kroner (approximately over ... -
European Drug Administration: Novo Nordisk says the shortage of diabetes drugs will last until 2024
[European Drug Administration: Novo Nordisk said that the shortage of diabetes drugs will last until 2024] The European Drug Administration (EMA) released a note on November 21 local time, saying tha ... -
Macron to announce Novo Nordisk's € 2.1 billion investment plan in France
On November 23rd, the Office of the French President revealed that French President Marcon would announce that Novo Nordisk plans to invest 2.1 billion euros in France, which is expected to create ov ... -
Novo Nordisk's "Weight Loss Medicine" Enters the Asian Market: Wegovy will be launched in Japan in February next year
Novo Nordisk, a Danish pharmaceutical giant, announced on Thursday (November 23) that it will launch its popular weight loss drug Wegovy in Japan on February 22 next year. This will be Novo Nordisk's ... -
Novo Nordisk CEO: Negotiating pricing agreement for weight loss drug Wegovy with healthcare system
Lars Fruergaard Jorgensen, CEO of Novo Nordisk, told the Financial Times that Novo Nordisk is in talks with the healthcare system about an innovative pricing agreement for its weight loss drug Wegovy ... -
Novo Nordisk is negotiating pricing agreements with healthcare systems in multiple countries for the "miracle weight loss medicine"
According to media reports, Danish pharmaceutical giant Novo Nordisk is negotiating an innovative pricing agreement for its weight loss drug Wegovy with healthcare systems in some countries. The comp ... -
Is the hype about weight loss pills over? Novo Nordisk's "dead bulls" have also begun to sell stocks significantly
A top performing European fund manager who has long held Novo Nordisk signals that the hype about weight loss pills should come to an end. Since the beginning of this year, the stock price of Novo No ... -
Novo Nordisk showcases multiple innovative cooperation achievements at the Chain Expo
The first China International Supply Chain Promotion Expo opened in Beijing on November 28th. Novo Nordisk showcased the three major chains of "R&D chain, manufacturing chain, and health chain" and t ... -
Novo Nordisk seeks to develop obesity prevention drugs
On December 5th, Novo Nordisk is conducting experiments and research to understand the causes of obesity and seeking to develop drugs to prevent obesity. -
Not only the miracle medicine for weight loss! Novo Nordisk's search for the development of "obesity prevention drugs" is still in its early stages of research
While pharmaceutical giants are still fiercely competing over GLP-1 weight loss drugs, Danish pharmaceutical giant Novo Nordisk has already set its sights on developing drugs to prevent obesity. -
Nearly 800 drugs in the United States collectively raise prices. Novo Nordisk's "weight loss miracle drug" has risen by 3.5%
Novo Nordisk and Lilly's GLP-1 diabetes drug prices were raised in the United States. On January 18, local time, it was reported that many pharmaceutical enterprises had increased the sales prices of ... -
Novo Nordisk plans to introduce weight loss oral small molecule drugs for 235 million euros
On January 23rd, Novo Nordisk announced a cooperation and licensing agreement with EraCal Therapeutics to develop and commercialize EraCal as a weight loss oral small molecule drug. It is reported th ... -
Novo Nordisk became the second European company with a market value of $500 billion after becoming LVMH
On January 31st, Novo Nordisk's stock price rose 3.1%, reaching a market value of $500 billion for the first time. Novo Nordisk became the second European company to reach a market value milestone of ... -
Novo Nordisk's net profit increased by 51% year-on-year in 2023, and the sales of "weight loss miracle drug" Wegovy increased by 407% year-on-year
On February 1st, Red Star Capital Bureau reported that Novo Nordisk (NVO.US) released its 2023 annual report, which showed that the company's annual revenue was approximately DKK 232.261 billion (app ... -
Smegglutide sells for over 20 billion US dollars and Novo Nordisk continues to expand production
On January 31st, Novo Nordisk released its 2023 financial report, with a total annual revenue of approximately DKK 232.261 billion (approximately USD 33.771 billion), a year-on-year increase of 31%; ... -
The market value has exceeded 500 billion US dollars! Behind the success of Novo Nordisk was a "gambling style" decision
Novo Nordisk official website Star pharmaceutical company Novo Nordisk once again gained market attention this week. On January 31st, this company, founded in 1923, achieved a significant milestone ...